Sanofi is France's national champion in the healthcare sector and now the overall #5 worldwide. It was formed in 2004 from the hostile takeover of French pharmaceutical giant Aventis by smaller rival Sanofi-Synthelabo. The merged group retained the Sanofi-Aventis name until 2011. A key factor in the takeover was the controversial role played by the French government which successfully steered Aventis away from a combination with Swiss-based Novartis in order to create a local champion that could compete more effectively with American and other European rivals. There have been several other small and medium-sized acquisitions since then. In 2007, the group was reported to have commenced merger talks with US group Bristol-Myers Squibb, which held local rights to Sanofi's Plavix drug, but no deal materialised. In 2009 the group established a presence in the consumer healthcare sector with the purchase of US company Chattem, and made an offer the following year to acquire biotech developer Genzyme. It added to its OTC portfolio in 2017 with a deal swapping its animal health division Merial for the consumer portfolio of German company Boehringer Ingelheim. Combined revenues for 2018 were €34.5bn; mostly from prescription pharmaceuticals, with €4.7bn from consumer healthcare and €5.1bn from vaccines division Sanofi Pasteur. Net income was €4.4bn. Sanofi agreed to sell its generics division Zentiva in 2018. Diabetes drug Lantus suffered a steep decline in 2018 as a result of patent expiry, but is still Sanofi's top-seller at €3.6bn. Other blockbusters include Aubagio for MS (sales of €1.6bn), and Lovenox and Plavix for thrombosis (€1.5bn and €1.4bn respectively). There are several other drugs just under blockbuster status including Toujeo, Myozyme and Fabrzyme. Fastest-growing product was Dupixent for severe allergies, which is expected to top €1bn in 2019. Key OTC brands include Allegra for allergies, painkiller Doliprane and cough/cold remedy Mucosolvan in Europe, laxative Dulcolax and skincare range Gold Bond in the US. In 2019, Sanofi secured US rights for a non-prescription version of Roche's antiviral Tamiflu. Vaccines include Menactra for meningitis and Fluzone. Olivier Brandicourt stepped down in 2019 after four years as CEO, to be replaced by former Novartis manager Paul Hudson.
Capsule checked 25th July 2019
Which agencies handle advertising for Sanofi? Find out more from the Account Assignments database.
Who are the competitors of Sanofi? See Pharmaceutical Sector index for other companies
Account assignments & selected contact information
Historical profile information for Sanofi
Adbrands Account Assignments track account management for the world's leading brands and companies, including details of which advertising agency handles which accounts in which countries for major markets.
Recent stories from Adbrands Update:
Adbrands Weekly Update 25th Jan 2018: French dug giant Sanofi inked its biggest deal for years with an agreement to acquire hemophilia specialist Bioverativ for a whopping $11.5bn. It is the group's biggest deal since 2011, when it bought Genzyme for $20bn, but the French group has also been pipped to the post in a number of other recent deals, losing Medivation in 2016 to Pfizer, and Actelion last year to Johnson & Johnson. At the same time, it faces an imminent generic threat to its top-selling product Lantus. Bioverativ's top-selling drugs are Eloctate and Alprolix. However, Sanofi will gain rights to them only in North America and Asia. Rights in the EMEA region are already owned by another company.
Adbrands Weekly Update 24th Aug 2017: There was another blow for Publicis Groupe's media division with the loss of the global account for French healthcare group Sanofi, which had been managed by the old ZenithOptimedia network. WPP's Mindshare becomes the main global agency in all markets except the US and Japan, and WPP will also add selected, as yet undisclosed creative responsibility alongside global incumbents Publicis and Havas. In the US, Havas Media will take over full responsibility for prescription pharmaceuticals, as well as planning for Sanofi's consumer healthcare portfolio, recently boosted by the acquisition of the equivalent division of German company Boehringer Ingelheim. Buying for the OTC business will remain with independent agency KWG, which also hands most creative for that unit. Combined global spend is around €900m.
Adbrands Weekly Update 24th Aug 2016: Pfizer trumped rival Sanofi by clinching a deal to acquire US drug developer Medivation, makers of the blockbuster prostate cancer drug Xtandi (co-marketed by Japanese company Astellas). Medivation was put in play after Sanofi launched a hostile bid for the company in June after several friendly approaches were rebuffed. The biotech developer sought white knight offers from US compatriots Pfizer and Amgen. Pfizer's $14bn deal is almost double Medivation's market cap before Sanofi's original approach.
Adbrands Weekly Update 7th July 2016: US drug developer Medivation, makers of top-selling prostate cancer drug Xtandi, softened its stance against French group Sanofi, whose several takeover offers it has repeatedly rejected. It also turned down the latest bid worth around $10bn, but agreed to open its books to the French group, as well as to two other suitors, Pfizer and Celgene. Separately, Sanofi agreed terms to transfer ownership of its animal health division Merial to German counterpart Boehringer Ingelheim, in return for the latter's OTC healthcare unit and €4.7bn in cash. Once that deal completes later this year, Boehringer will become the world's second largest animal health company behind Zoetis with sales of around €3.8bn. Sanofi's enlarged consumer healthcare division would have sales in excess of €4.9bn.
Adbrands Weekly Update 12th May 2016: French drug giant Sanofi launched a hostile takeover for US oncology developer Medivation after attempts to lure the smaller company into negotiations failed. The latter has enjoyed considerable success with prostate cancer treatment Xtandi, co-marketed by Japan's Astellas, and it has a couple of other promising drugs in the pipeline. However Sanofi's opening offer of $52.50 per share - around $9.3bn total - was spurned by Medivation, and markets have already pushed up the smaller company's shares over $60. Some analysts believe it could be worth as much as $70 to the right buyer. Sanofi indicated it may go higher, but only if Medivation will enter negotiations. Yet the target company has continued to spurn its French suitor. According to Reuters, it will instead allow US companies Pfizer and Amgen to begin preliminary due diligence.
All rights reserved © Mind Advertising Ltd 1998-2019